iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that a poster featuring preclinical data related to its tetravalent anti-GITR agonist antibody, FPA154, will be presented during the Society for Immunotherapy of Cancer (SITC) Annual Meeting, on November 11, 2016, in National Harbor, Maryland. Poster #175 titled, “Novel tetravalent anti-GITR antibody is a potent anti-tumor agent in vivo,” will be made available at http://www.fiveprime.com/news-media/publications-presentations following the presentation.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding Five Prime's potential receipt of upfront and milestone payments and royalties. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
CONTACTS: Heather Rowe Investor Relations 415-365-5737 [email protected] Amy Kendall Corporate Communications 415-365-5776 [email protected]
